Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 1
1994 1
1995 1
1996 2
1997 1
1998 1
2011 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, et al. von der Leyen H, et al. Among authors: wenzlaff h. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. doi: 10.1007/BF00167387. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1723153
Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Bethke T, Klimkiewicz A, Meyer W, Schumacher C, Schmitz W, Scholz H, Starbatty J, Wenzlaff H, Zimmermann W. Bethke T, et al. Among authors: wenzlaff h. Arzneimittelforschung. 1995 Jul;45(7):771-6. Arzneimittelforschung. 1995. PMID: 8573220
11 results